Toll-Like Receptor 4

"Toll-Like Receptor 4" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A pattern recognition receptor that interacts with LYMPHOCYTE ANTIGEN 96 and LIPOPOLYSACCHARIDES. It mediates cellular responses to GRAM-NEGATIVE BACTERIA.

Descriptor ID	D051197
MeSH Number(s)	D12.776.543.750.705.910.500.400
Concept/Terms	Toll-Like Receptor 4 Toll-Like Receptor 4 Toll Like Receptor 4 Toll-4 Receptor Toll 4 Receptor TLR4 Receptor Receptor, TLR4

Below are MeSH descriptors whose meaning is more general than "Toll-Like Receptor 4".

Chemicals and Drugs [D]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptors, Immunologic [D12.776.543.750.705]
Receptors, Pattern Recognition [D12.776.543.750.705.910]
Toll-Like Receptors [D12.776.543.750.705.910.500]
Toll-Like Receptor 4 [D12.776.543.750.705.910.500.400]

Below are MeSH descriptors whose meaning is related to "Toll-Like Receptor 4".

Below are MeSH descriptors whose meaning is more specific than "Toll-Like Receptor 4".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Toll-Like Receptor 4" by people in this website by year, and whether "Toll-Like Receptor 4" was a major or minor topic of these publications.

Bar chart showing 38 publications over 18 distinct years, with a maximum of 5 publications in 2011

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2002	0	1	1
2003	0	1	1
2005	1	1	2
2006	2	2	4
2008	1	0	1
2009	1	0	1
2010	1	2	3
2011	1	4	5
2012	3	1	4
2013	1	1	2
2014	0	1	1
2015	1	0	1
2016	1	1	2
2017	1	1	2
2018	2	0	2
2020	2	0	2
2022	0	1	1
2024	2	1	3

Below are the most recent publications written about "Toll-Like Receptor 4" by people in Profiles.

Alugupalli KR. Characterization of Turbo, a TLR Ligand-based Adjuvant for Glycoconjugate Vaccines. Immunohorizons. 2024 Aug 01; 8(8):527-537.

View in: PubMed
Alugupalli KR. A TLR4 ligand-based adjuvant for promoting the immunogenicity of typhoid subunit vaccines. Front Immunol. 2024; 15:1383476.

View in: PubMed
Alugupalli KR. Monophosphoryl Lipid A-based Adjuvant to Promote the Immunogenicity of Multivalent Meningococcal Polysaccharide Conjugate Vaccines. Immunohorizons. 2024 Apr 01; 8(4):317-325.

View in: PubMed
Palatnik-de-Sousa I, Wallace ZS, Cavalcante SC, Ribeiro MPF, Silva JABM, Cavalcante RC, Scheuermann RH, Palatnik-de-Sousa CB. A novel vaccine based on SARS-CoV-2 CD4+ and CD8+ T cell conserved epitopes from variants Alpha to Omicron. Sci Rep. 2022 10 06; 12(1):16731.

View in: PubMed
L?pez-Haber C, Levin-Konigsberg R, Zhu Y, Bi-Karchin J, Balla T, Grinstein S, Marks MS, Mantegazza AR. Phosphatidylinositol-4-kinase IIa licenses phagosomes for TLR4 signaling and MHC-II presentation in dendritic cells. Proc Natl Acad Sci U S A. 2020 11 10; 117(45):28251-28262.

View in: PubMed
Novak T, Hall MW, McDonald DR, Newhams MM, Mistry AJ, Panoskaltsis-Mortari A, Mourani PM, Loftis LL, Weiss SL, Tarquinio KM, Markovitz B, Hartman ME, Schwarz A, Junger WG, Randolph AG. RIG-I and TLR4 responses and adverse outcomes in pediatric influenza-related critical illness. J Allergy Clin Immunol. 2020 06; 145(6):1673-1680.e11.

View in: PubMed
Andrade-Silva M, Cenedeze MA, Perandini LA, Felizardo RJF, Watanabe IKM, Agudelo JSH, Castoldi A, Gon?alves GM, Origassa CST, Semedo P, Hiyane MI, Foresto-Neto O, Malheiros DMAC, Reis MA, Fujihara CK, Zatz R, Pacheco-Silva A, C?mara NOS, de Almeida DC. TLR2 and TLR4 play opposite role in autophagy associated with cisplatin-induced acute kidney injury. Clin Sci (Lond). 2018 08 31; 132(16):1725-1739.

View in: PubMed
Roedig H, Nastase MV, Frey H, Moreth K, Zeng-Brouwers J, Poluzzi C, Hsieh LT, Brandts C, Fulda S, Wygrecka M, Schaefer L. Biglycan is a new high-affinity ligand for CD14 in macrophages. Matrix Biol. 2019 04; 77:4-22.

View in: PubMed
Marshall NB, Lukomska E, Nayak AP, Long CM, Hettick JM, Anderson SE. Topical application of the anti-microbial chemical triclosan induces immunomodulatory responses through the S100A8/A9-TLR4 pathway. J Immunotoxicol. 2017 Dec; 14(1):50-59.

View in: PubMed
Hsieh LT, Nastase MV, Roedig H, Zeng-Brouwers J, Poluzzi C, Schwalm S, Fork C, Tredup C, Brandes RP, Wygrecka M, Huwiler A, Pfeilschifter J, Schaefer L. Biglycan- and Sphingosine Kinase-1 Signaling Crosstalk Regulates the Synthesis of Macrophage Chemoattractants. Int J Mol Sci. 2017 Mar 09; 18(3).

View in: PubMed

People

Explore

Similar Concepts

Top Journals

The Thomas Jefferson University web site, its contents and programs, is provided for informational and educational purposes only and is not intended as medical advice nor is it intended to create any physician-patient relationship. Please remember that this information should not substitute for a visit or a consultation with a health care provider. The views or opinions expressed in the resources provided do not necessarily reflect those of Thomas Jefferson University, Thomas Jefferson University Hospital, or the Jefferson Health System or staff.
Please read our Privacy Statement